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KAJIAN ANALITIKAL, BIOAKTIVITI DAN STABILITI TERHADAP EKSTRAK 
STROBILANTHES CRISPUS L. BREMEK DAN SONCHUS ARVENSIS L. 
ABSTRAK 
Tujuan kajian ini adalah untuk memiawaikan ekstrak-ekstrak (Ew, E7ac, Em, 
Eac dan Em-sox) daun Strobilanthes crispus L. Bremek dan Sonchus arvensis 
L. untuk tujuan kajian praklinikal. Kaedah pemiawaian dibahagikan kepada tiga 
bahagian iaitu profil kimia (kajian analitikal dan fitokimia), profil biokimia (kajian 
perencatan pertumbuhan kristal, antioksidan dan kestabilan) dan profil biologi 
(kajian antiangiogenik). 
Sebatian metabolit sekunder yang dikesan dalam daun S. crispus ialah α-
sitosterol, campesterol, phytol dan stigmasterol, sementara lupeol, phytol dan α-
sitosterol dikesan dalam daun S. arvensis. Sebatian tritriakontana dan 
stigmasterol telah diasingkan daripada daun S. crispus, sementara lupeol dan 
kuersetin telah diasingkan daripada daun S. arvensis.  
Indeks perencatan ekstrak Ew, E7ac, Em, Eac, dan Em-sox S. crispus terhadap 
perencatan pertumbuhan kristal kalsium oksalat masing-masing adalah 0.2233 
± 0.0875, 0.1861 ± 0.0124, 0.1587 ± 0.0264, 0.1830 ± 0.0335, dan 0.2081 ± 
0.0166. Manakala indeks perencatan ekstrak yang sama daripada S. arvensis 
masing-masing adalah 0.3375 ± 0.0157, 0.1994 ± 0.0257, 0.1938 ± 0.0662, 
0.1347 ± 0.0439, dan 0.3157 ± 0.0457.  
Aktiviti antioksidan tertinggi ke atas aktiviti radikal bebas, aktiviti xantina 
oksidase dan pelunturan β-karotena oleh asid linoleik daripada ekstrak S. 
crispus masing-masing adalah E7ac, Em dan Em-sox. Manakala bagi yang 
sama daripada ekstrak S. arvensis masing-masing adalah E7ac, Eac dan Em.  
 xxvii
Peratusan fenolik daripada ekstrak tumbuh-tumbuhan ini juga ditentukan. 
Koefisien penentuan (R2) antara kandungan fenolik dan aktiviti radikalnya 
adalah  0.93 (S. arvensis) dan 0.40 (S crispus). Dalam perencatan pelunturan 
β-karotena oleh asid linoleik, didapati kesan protein lebih besar berbanding 
kesan polisakarida.  
Dalam kajian kestabilan dipercepat, kesemua ekstrak (Ew, Em, and Eac) yang 
disimpan pada suhu bilik (25 0C, 60% RH) adalah tertinggi berbanding ekstrak 
yang disimpan pada suhu 40 0C (75%RH), 50 0C (85% RH) dan 60 0C (85% 
RH). Jangka hayat (t90) ekstrak Eac, Em dan Ew daripada S. crispus yang 
disimpan pada suhu bilik, masing-masing adalah 2.14, 2.17 dan 1.94 bulan. 
Manakala t90 ekstrak yang sama daripada S. arvensis masing-masing adalah 
2.10, 7.89 dan 3.50 bulan. t90 stigmasterol dalam Em dan Eac daripada S. 
crispus yang disimpan pada suhu bilik, masing-masing adalah 3.60 dan 2.63 
bulan. Manakala t90 lupeol dalam ekstrak Em dan Eac daripada S. arvensis, 
masing-masing adalah 2.51 dan 2.22 bulan. 
Dalam kajian awal antiangiogenik, keputusan menunjukkan bahawa peratus 
perencatan Ew dan Em daripada S. crispus, masing-masing adalah 16.67 dan 
6.25%, manakala peratus perencatan Ew dan Em daripada S. arvensis, 
masing-masing adalah 11.06 dan 8.65%, memperlihatkan bahawa kedua 
tumbuhan ini mempunyai kemampuan mencegah atau menyembuh penyakit-
penyakit yang berkaitan dengan angiogenik.  
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ANALYTICAL, BIOACTIVITY AND STABILITY STUDIES ON STROBILANTHES 
CRISPUS L. BREMEK AND SONCHUS ARVENSIS L. EXTRACTS 
ABSTRACT 
The purpose of this study was to standardize the leaf extracts (Ew, E7ac, Em, 
Eac and Em-sox) of Strobilanthes crispus L. Bremek and Sonchus arvensis L. 
for preclinical studies. The standardization work was divided into three steps: 
chemical profiling (analytical and phytochemical studies), biochemical profiling 
(crystal growth inhibition, antioxidant and stability studies) and biological 
profiling (antiangiogenic studies).  
Secondary metabolites detected in S. crispus leaves were α-sitosterol, 
campesterol, phytol and stigmasterol, whereas lupeol, phytol and α-sitosterol 
were detected in S. arvensis leaves. Tritriacontane and stigmasterol were 
isolated from S. crispus leaves whilst lupeol and quercetin were isolated from S. 
arvensis leaves.  
The inhibition indices of Ew, E7ac, Em, Eac, and Em-sox from S. crispus to 
inhibit the growth of calcium oxalate crystals were 0.2233 ± 0.0875, 0.1861 ± 
0.0124, 0.1587 ± 0.0264, 0.1830 ± 0.0335, and 0.2081 ± 0.0166, respectively. 
The values for similar extracts for S. arvensis were 0.3375 ± 0.0157, 0.1994 ± 
0.0257, 0.1938 ± 0.0662, 0.1347 ± 0.0439, and 0.3157 ± 0.0457, respectively. 
The highest antioxidant activity on FRSA to DPPH, xanthine oxidase activity 
and prevention the bleaching of β-carotene by linoleic acid of S. crispus extracts 
are E7ac, Em and Em-sox, respectively whilst those of S. arvensis extracts are 
E7ac, Eac and Em, respectively. The percentages of phenolic content from 
these plants extract were also determined. Coefficient value (R2) between their 
phenolic content and FRSA were 0.93 (S. arvensis) and 0.40 (S crispus). In the 
 xxix
prevention of bleaching of β-carotene by linoleic acid, effect of protein was more 
than that of polysaccharide. 
In accelerated stability studies, the extracts (Ew, Em, and Eac) stored at room 
temperature (25 0C, 60% RH) was highest when compared to stored at 40 0C 
(75%RH), 50 0C (85% RH) and 60 0C (85% RH). Shelf life (t90) of Eac, Em and 
Ew from S. crispus stored at room temperature was 2.14, 2.17 and 1.94 
months, respectively. Meanwhile the t90 of similar extracts from S. arvensis was 
2.10, 7.89 and 3.50 months, respectively. The t90 of stigmasterol in Em and Eac 
from S. crispus stored at room temperature was 3.60 and 2.63 months 
respectively, whilst lupeol in Em and Eac from S. arvensis was 2.51 and 2.22 
months respectively. 
In preliminary antiangiogenic studies, the results showed that inhibition 
percentages of Ew and Em from S. crispus are 16.67 and 6.25% respectively, 
whilst those of Ew and Em from S. arvensis are 11.06 and 8.65% respectively, 
exhibiting that these plants possess the potential to prevent or cure 
angiogenesis related diseases.  
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CHAPTER 1 
INTRODUCTION 
1. 1 The Usage of Medicinal Plants 
Plants have been used as source of medicines for thousands of years in 
maintaining health as an alternative to or in conjunction with modern medicines. 
The majority of the world's population in developing countries used herbal 
medicines to meet their health needs, following traditional beliefs and practices 
adopted from their elders and ancestors. The World Health Organization (WHO) 
estimated about 70% of the world population uses medicinal plants for 
medicines, and they are highly used mainly in Asia, South America and Africa 
(Chapman, K. and Chomchalow, N., 2005). Mamedov et al. (2005) reported the 
flora of Russia and Central Asia contains approximately 300 species of plants 
that have been used in prescription and non-prescription pharmaceutical 
preparations, while nearly 2500 plants are known to have been used in 
traditional medicine. A study from Kenya showed that patients had a clear 
sense of which diseases when they visit a traditional healer although previously 
they would go to a western clinic. In South Africa, traditional healers are 
flourishing in urban areas where western health care is also available (Van der 
Geest, 1997; Mander et al., 1997 cited in Jäger, A. K., 2005). Another study 
reported that the rate of having used an alternative treatment method is  42.1% 
in the U.S, 48% in Australia, 70% in Canada, 38% in Belgium, 90% in Germany, 
75% in France and 75.9% in Turkey (Recai et al., 2006). Meanwhile, Lai et al. 
(2007) reported that over two-thirds of the older Chinese immigrants in Canada 
use traditional Chinese medicine in combination with Western health services. 
About half (50.3%) of the older Chinese immigrants used Chinese herbs, 48.7% 
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used Chinese herbal formulas, and 23.8% consulted a Chinese herbalist. In 
Indonesia, Sulaksana et al. (2004) reported that at least 1,845 of medicinal 
plants have been identified and inventoried, and at least 400 ethnic 
communities have experiences in use of medicinal plants.  
 
The use of herbal medicine is extensive, increasing and complex. In England, 
from a survey of the use of complementary and alternative medicine (CAM) 
reported that purchasing of herbal medicine product (HMPs) have increased 
almost 20% per year (Heinrich et al., 2004). In 2002, the global trade in herbal 
product to have a value of US$12 billion, with trades in crude medicinal plants 
exceeding US $800 M., herbal extracts and semi-finished raw materials 
exceeding US $8 billion and herbal cosmetics about US$1.5 billion (Parke and 
Tikasingh, 2002). The demand for medicinal plants is increasing everyday and 
the World Health Organization (WHO) has projected that the global herbal 
market will grow to $5 trillion by 2050 from the current level of $62 billion with 
growth rate of 7 to 30 per cent annually (Reddy, 2003). According to Malaysian 
Deputy Minister of Natural Resources and Environment, currently the value of 
the local herbal market in Malaysia is estimated to be around 3.8 billion Ringgit 
(1.03 billion U.S. dollars) and this amount is expected to reach 8 billion Ringgit 
(2.16 billion U.S. dollars) by 2010, a handsome annual growth rate of 15 to 20 
percent (http://english.people.com.cn/ 200609/13/eng20060913_302302.html). 
 
In addition, combination of traditional and modern medicine has an important 
role in promoting health care system. In many countries, herbal medicine is 
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making a strong comeback and the world of medicine today embraces both 
single pure chemical entities and herbal medicine side by side (WHO, 2001).   
 
There are many medicinal herbs used in health care, such as Eurycoma 
longifolia, Orthosiphon stamineus, Phyllanthus niruri, Andrographis paniculata, 
and Catharanthus roseus (Wiart, 2002; Zakaria and Ali, 1994; Dalimartha, 
1999). To enable medicinal plants to be use in modern medicine, researches 
and development are important for the advancement of traditional medicines.  
 
My research work will focus on two widely used medicine plant species, 
Strobilanthes crispus and Sonchus arvensis. Both of the latter has their origins 
from Padang Sumatera. 
1.2 Strobilanthes crispus Plant 
1.2.1 Botanical Description  
Strobilanthes crispus L. Bremek is an annual plant, which grows easily in the 
forest, riverbanks and abandoned fields. It is commonly used as fence hedges. 
The plant is native to countries from Madagascar to Indonesia, which can be 
grown 50 to 1200 meters above sea level. This bush-like plant can attain a 
height between 1 to 2 m. The circular bark can be divided into segments and 
similar to its branches, they are hairy and green. The leaf is oblong-lanceolate, 
rather obtuse, and shallowly crenate-crispate. The top surface of the leaf is 
darker green in color and less rough compared to the under surface. The leaves 
are very scabrous on both surfaces and covered with short hairs, whereas the 
flower is short, dense, and consists of penciled spikes. The leaf is 9-18 cm in 
length and 3-8 cm in width. The plant can be propagated using cut steams. 
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The classification for S. crispus is as follows, Division is Spermatophyta, Sub 
division is Angiospermae, Class is Dicotyledonae, Sub class is Solanales, 
Family is Acanthaceae, Genus is Strobilanthes and Species is Strobilanthes 
crispus. 
The local name is daun picah beling (Jakarta), enyoh kelo, kecibeling, 
kejibeling, ngokilo (Java), pecah kaca or jin batu (Malay). The Latin synonym is 
Sericocalyx crispus L. Bremek (Departemen Kesehatan Republik Indonesia, 
19771; Syamsuhidayat and Hutapea, 19911; Wijayakusuma et al., 2000; Heyne, 
1987; Fadzelly et al., 2006). Picture of S. crispus is presented in Plate 1.1. 
 
 
        Plate 1.1 Picture of S. crispus plant 
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1.2.2 Biological Activity  
Studies in Indonesia have found that infusion of the dried leaves has been used 
as antidiabetic, diuretic, antilithic, and laxative (Perry and Metzger, 1980; 
Syamsuhidayat and Hutapea, 19911; Wijayakusuma et al., 2000). They 
suggested boiling 25 – 50g of fresh leaves in 200 ml boiling water, and then 
drinking the infusion after filtration. For external use, poultice of the fresh leaves 
can be directly applied on to wounds caused by the bite of poisonous snakes or 
other animals (Wijayakusuma et al., 2000). Ismail et al., (2000) reported that the 
extract showed antioxidant activity using ferric thiocyanate (FTC) and 
thiobarbituric acid (TBA) methods. Jaksa et al. (2004) reported that the extract 
showed anti hepatocarcinogenesis effect on rats. The hot water-extract of 
fermented and unfermented leaves was found to reduce blood glucose in 
hyperglycemic rats, while unfermented leaves also reduced glucose level in 
normal rats. Both fermented and unfermented leaves also exhibited improved 
lipid profiles (Fadzelly et al., 2006). Rahmat et al. (2006) reported that the 
methanolic extract displayed strong cytotoxic effect on colon cancer (Caco-2), 
human breast cancer hormone non-dependent (MDA-MB-231) and liver cancer 
(HepG-2). The chloroform extract of this plant was also shown to have cytotoxic 
effect against Caco-2 and HepG-2.  
1.2.3 Phytochemistry 
Soediro et al. (1983, 1988) isolated and identified verbacoside, glycosidic ester 
of caffeic acid and seven phenolic acids; namely p-hydroxy benzoic, p-
coumaric, caffeic, vanilic, gentinic, ferulic, and syryngic acids in the leaves. 
Besides, the leaves also contained tannin, saponin, salt of potassium, sodium 
and silicate (Departemen Kesehatan Republik Indonesia, 19771, 1980; 
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Syamsuhidayat and Hutapea, 19911; Wijayakusuma et al., 2000). Rahmat et al. 
(2006) reported the presence of β-sitosterol, and stigmasterol in the leaves. The 
chemical structures of the constituents are presented in Fig. 1.1.  
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1.3 Sonchus arvensis Plant 
1.3.1 Botanical Description 
S. arvensis L. is an annual plant that is easy to grow in rainy and sunshine 
areas, such as on riverbanks, ridges of rice field and abandoned fields 50 – 
1650 meters above sea level. The plant is a native of Eurasia with a tapered 
root and produces bitter latex. The stem is hollow inside. The leaves are single, 
6 – 48 cm in length and 3 – 12 cm in width, elliptical, and lanceolate in shape, 
highly variable, entire to deeply pinnate-lobed, clasping the stem at the base 
with rounded basal lobes (auricles), sharp-pointed at end side, while at the base 
is like heart, and green in color.  
Flowers are humped shape and having a long stalk, light yellow in color and 
turns brownish red on maturity. The fruits are thin box shape with five sides, 4 
mm in length, hairy and yellowish brown in color. The plants can be propagated 
using the seeds.  
The classification for Sonchus arvensis is as follows: Division is Spermatophyta, 
Sub division is Angiospermae, Class is Dicotyledonae, Sub class is Asterales, 
Family is Asteraceae, Genus is Sonchus, and Species: Sonchus arvensis. 
The local name is lempung, rayana, jombang and galibug, lalakina (Sunda), 
tempuyung (Jawa). Other names are Niu she tou (China), Laitron des champs 
(France), Sow thistle (British) (Dalimartha, 2001; Departemen Kesehatan 
Republik Indonesia, 19772; Sulaksana et al., 2004; Syamsuhidayat and 
Hutapea, 19912; Wijayakusuma et al., 2001). Picture of S. arvensis is presented 
in Plate 1.2. 
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1.3.2 Biological Activity 
S. arvensis L. is one of the medicinal herbs used in traditional medicines, in 
which the leaf extract was used as a diuretic, lithotriptic and antiurolithiasis 
agent; also indicated for fever, poisoning and swelling or abscess (Dalimartha, 
2001; Syamsuhidayat and Hutapea, 19912). Dalimartha (2001) recommended 
using 15 – 60 g fresh leaves, boiled in water, and the filtered infusion taken as 
medicine. For external use, the ground fresh leaves were applied directly on the 
wounds or the pressed liquid can be used as a compress for abscess, injured 
skin and wasir (Dalimartha, 2001).  
 
 
Plate 1.2 Picture of S. arvensis plant. 
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1.3.3 Phytochemistry 
From the leaves of S. arvensis several compounds have been isolated and 
identified, including luteolin, luteolin-7-O-glucoside (Bondarenko et al., 1973), 
isocinaroside (Bondarenko et al., 1974), luteolin-7-O-glucoside, linarin 
(Bondarenko et al., 1975), quercetin, isorhamnetin, chrysoeriol, isorhamnetin-7-
β-D-glucoside, quercetin-7-β-D-glucopyranoside (Bondarenko et al., 1976), 
sonchoside (Bondarenko et al.,  1978), and apigenin, luteolin-7-O-glucoside (Qu 
Guirong et al.,1993), acacetin, kaempferol, chrysoeriol, luteolin, isorhamnetin 
(Qu Guirong et al., 1995), quercetin-3-O-α-L-rhamnoside, kaempferol-3,7-α-L-
dirhamnoside (Qu, Guirong et al., 1996), α-amyrin, β-amyrin, lupeol, 
taraxasterol (lactuserol), pseudo-taraxasterol (Hooper et al., 1982). The leaves 
also contain manitol, inositol, silica, potassium and saponin (Fig. 1.2).  
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Fig. 1.2 Chemical structures of S. arvensis constituents 
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Fig. 1.2 (continued) 
 
 
1.4. Analysis and Isolation of the Chemical Constituents 
The purpose of this analysis is to determine the presence of substances in a 
sample, qualitative or quantitatively. In this study, the aim of the isolation is to 
obtain compound/s useful as chemical marker. 
 
“Markers are constituents of medicinal plant material that are chemically defined 
and are of interest for control purpose.  Markers are generally used when 
constituents with known therapeutic activity are not found or are uncertain and 
may serve to calculate the quantity of plant material or preparation in the 
finished product. However, the marker has to be quantitatively determined in the 
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plant material or preparation when the starting materials are tested” (WHO, 
1993).  
 
“Chemical constituents in plant vary depending on the genetic heterogeneity of 
plant species, part of plant, differences in conditions of growth, the age of the 
plant, the time and manner of collection or harvest, method of processing and 
storage, shelf life and interaction with the other plant constituents. Furthermore, 
identification and characterization of the structure of unknown substances are 
an important part of natural product drug analysis” (Cannell, 1998). 
1.5 Kidney Stone Disease 
1.5.1 Aspects of Kidney Stone Disease 
Kidney stones are not a product of modern life, but the Scientists have found 
evidence of kidney stones in a 7,000-year-old Egyptian mummy. In year 2000, 
2.7 million of patients visited health care centers and of these more than 
600,000 patients were found to suffer from kidney stone. Men tend to be 
affected more frequently than women. Prevalence of kidney stone rises for men 
in their 40s and this continues until they are in their 70s, whilst women tend to 
suffer disease during their 50s (Coe, 2004). 
 
A kidney stone is a hard mass developed from crystals that separate from the 
urine and build up on the inner surfaces of the kidney. Urine normally contains 
chemicals that can inhibit the crystal formation. These chemicals may not 
function effectively in certain cases leading to stone formation. Fine stone may 
pass out of the body through the urinary tract. The chemical composition of 
kidney stones depends on the chemical imbalance in the urine. There are four 
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types of kidney stones i.e. calcium, uric acid, struvite and cystine stones. 
Calcium type is predominantly stone, approximately 80%, and the most 
common type of stone in combination with either oxalate or phosphate. Struvite 
called infection stone is a less common followed by uric acid stone which is the 
least common of all. Cystine stones are also very rare (Coe, 2004; Hesse et al., 
1976) 
1.5.2 Natural Product Inhibitor of Urinary Calculi 
Traditionally, some plants were found to be acceptable in treating kidney stone 
and related kidney disorders, for example, Orthosiphon stamineus Benth, 
Strobilanthes crispus L. Bremek, Soncus arvensis L., Malpighia coccigera and 
genus Phyllanthus were used (Perry and Metzger, 1980). The plants used 
traditionally in kidney stone diseases are presented in Table 1.1. 
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Table 1.1 Plants used for treatment of kidney stone and related diseases  
No Plant Name Constituent Reference 
1 Plantago 
major 
Glycoside aucubin, plantagin, plantenolic, 
succinic acid, adenine, cholin, and aucubin. 
Polysaccharides, lipids, cafeic acid 
derivatives, flavonoids, iridoid glycosides, 
terpenoids, alkaloid, organic acid.  
Perry and Metzger, 
1980; Samuelsen, 
2000. 
2 Zea mays  Galactan, xylan, dextrose, sugar, 
zeaxanthin, protein, inosite, 
hexaphosphoric acid, maizenic acid, resins, 
potassium and calcium salt. Anthocyanins 
cyanidin-3-glucoside, pelargonidin-3-
glucoside etc. Phenolic acid p-coumaric 
acid, vanillic acid etc. 
Perry and Metzger, 
1980; Pedreschi 
and Cisneros, 
2007; Pozo-Insfran 
et al., 2006 
3 Raphanus 
sativus  
Acylated anthocyanin (as pelargonidin), 
alkaloids pyrolidine, isoquinoline, 
phenethylamine, sulphuric compounds 
glucoparin, sinigrin, allylisothiocyanate. 
Flavonoids apigenin, apigenin-7-O-
triglycoside etc.  
Otsuki et al., 2002 ; 
Vargas et al., 1999; 
Basile et al., 2003. 
4 Phylanthus 
niruri 
Potassium, phyllanthin, hypophyllanthin, 
triacontanal, triacontanol, lignans, 
glycosides, flavonoids, alkaloids, tannins, 
phenylpropanoids, saponins 
Perry and Metzger, 
1980; 
Syamasundar et 
al., 1985 
5 Orthosiphon 
stamineus 
High potassium salt, glucoside, diterpenes, 
orthosiphols, rosmarinic acid, salvigenin, 
orthosiphols, flavonoids (eupatorin, 
sinensitin, 3′-hydroxy-5,6,7,4′-
tetramethoxyflavone,TMF) 
Perry and Metzger, 
1980; Takeda et 
al., 1993; Akowuah 
et al., 2005 
 
1.6 Antioxidant 
1.6.1 Aspect and Process of Antioxidation 
An antioxidant is a chemical or any substance or any enzyme that prevents or 
reduces the oxidation or oxidative damage due to oxygen or other chemicals. 
All living organisms contain complex systems of antioxidant enzymes and 
chemicals. Antioxidants in biological systems have multiple roles and these 
include deterring oxidative damage and participating in the major signaling 
pathways of the cells. One major action of antioxidants in cells is to prevent 
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damage due to the action of reactive oxygen species (ROS) involved hydrogen 
peroxide (H2O2), the superoxide anion (O2•−), and free radicals such as the 
hydroxyl radical (•OH). These molecules are unstable and highly reactive, and 
can damage cells by chemical chain reactions such as lipid peroxidation, or 
formation of DNA adducts that could cause cancer-promoting mutations or cell 
death (Ames et al., 1993; Finkel and Holbrook, 2000). Oxidative stress, induced 
by oxygen radicals, is believed to be a primary factor in various degenerative 
diseases, such as cancer (Muramatsu et al., 1995), atherosclerosis (Steinberg 
et al., 1989), gastric ulcer (Das et al., 1997). 
The classification of antioxidants is one of two ways, i.e. chain-breaking and 
preventive. In the chain-breaking event, a free radical releases or steals an 
electron leading to the formation of a second radical. This molecule in turn 
follows the same path that leads to the formation of a third molecule. This 
process repeats itself leading to the generation of more unstable products. The 
process continues until the radical is stabilized by a chain-breaking antioxidant 
or it simply decays into a harmless product. In preventive, antioxidant enzymes 
like superoxide dismutase, catalase and glutathione peroxidase prevent 
oxidation by reducing the rate of chain initiation (Parnes, 1998). In the works, 
antioxidants reduce the free radical energy, stop the free radical from forming in 
the first place, or interrupt an oxidizing chain reaction to minimize the damage 
caused by free radicals (Ames et al., 1993). 
1.6.2 Systems of Antioxidation 
These systems can be divided into enzymatic and non enzymatic. The 
enzymatic involved superoxide dismutase (SOD), which catalyses such as the 
conversion of O2●⎯ to H2O2 and H2O, and then convert H2O2 to H2O and O2.    
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Meanwhile non enzymatic involved the lipid-soluble vitamin for example 
vitamins E and A or provitamin A (β-carotene) (Fouad, 2007). 
The example of enzymatic antioxidant is xanthine oxidase (XO), which is a very 
important enzyme in the purine metabolism involved in the formation of uric acid 
in the body, i.e. catalyzes the oxidation of hypoxanthine to xanthine and can 
further catalyze the oxidation of xanthine to uric acid. XO is responsible for the 
medical condition known as gout. Gout is caused by deposition of uric acid in 
the joints leading to painful inflammation, with inhibition of XO leading to a 
remission in gout.  
 
The active site of XO is composed of a molybdopterin unit with the molybdenum 
atom also coordinated by terminal oxygen (oxo) and sulfur atoms and a terminal 
hydroxide. In the reaction with xanthine to form uric acid, an oxygen atom is 
tranferred from molybdenum to xanthine. The reformation of the active 
molybdenum center occurs by the addition of water. Like other known 
molybdenum-containing oxidoreductases, the oxygen atom introduced to the 
substrate by XO originates from water rather than from dioxygen (O2) (Chiang 
et al., 1994; Hille, 2005; Harrison, 2002; Rastelli et al., 1997; Parnes, 2006). 
Xanthinuria, hypouricemia, hypercalcinuria, and decreased bone density are the 
diseases caused by insufficient function of xanthine oxidase. Similar symptoms 
are increased xanthine excretion, decreased uric acid excretion, and mental 
retardation. One proposed hypothesis says that drinking tea decreases the risk 
of cancer because of the presence polyphenols which are know as inhibitors of 
xanthine oxidase (Xu et al., 1994). Some dietary phenolic compounds might 
function as natural biological response modifier (BRM) by protecting cells or 
 16
tissues against injuries especially those caused by lipid peroxidation and/or 
enzyme mediated oxidation (Nakagami et al., 1995). 
 
The followings are example of non enzymatic antioxidant: 
a. Free Radicals 
Free radicals are believed to play a role in different health conditions, including 
the aging process, cancer, and atherosclerosis. Reducing exposure to free 
radicals and increasing intake of antioxidant nutrient has the potential to reduce 
the risk of free radical-related health problem.  
In the free radical scavenging activity using 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) assay, the purple colored DPPH constitute the stable free radical, 
which is reduced to 1,1- diphenyl-2-picrylhydrazine (yellow colored) by reacting 
with an antioxidant The antioxidant donates hydrogen from the hydroxyl group 
to free radical (DPPH) to inhibit the chain oxidation by the free radical. The 
product is a stable molecule, which will not initiate or propagate further oxidation 
of lipids (Sherwin, 1978; Blois, 1958). 
b. β-Carotene 
β-Carotene is a member of a class of substance called carotenoids is a vitamin 
that acts as an antioxidant, protecting cells against oxidation damage. Some 
studies have showed differences in the in vitro activities of the β-carotene 
isomers. One study showed that 9-cis β-carotene that isolated from Dunaliella 
bardawil has higher potency to protect methyl linoleate from oxidation than that 
of the all-trans β-carotene isomer (Levin and Mokady, 1994). Another study 
demonstrated that 9-cis β-carotene and all-trans β-carotene had equal 
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antioxidant activities when assessed by enhanced human neutrophil 
chemiluminescence (Liu et al., 2000). 
1.6.3 Nutritional Antioxidants 
The following substances are example of nutritional antioxidant: 
a. Vitamins: Vitamin A, C (ascorbic acid), E.  
The example of food containing high levels of these antioxidants is fruits, 
vegetables and vegetable oils. Vitamins are believed to play a role in preventing 
the development of such chronic diseases as cancer, heart disease, stroke, 
memory loss, rheumatoid arthritis, and cataracts (Parnes, 1998). Low dietary 
intake of antioxidant vitamins and minerals increase the incidence rate of 
cardiovascular disease and cancer (Hercberg et al., 2004) 
b. Carotenoid terpenoids (α-carotene, β-carotene).  
Carrot is the example of food containing carotenoids.  
c. Flavonoid and polyphenolics.  
Food containing of these antioxidant are tea, coffee, chocolate, fruits and 
soy. Flavonoids have a variety of biological effects in numerous mammalian cell 
systems, in vitro as well as in vivo. Recently much attention has been paid to 
their antioxidant properties and to their inhibitory role in various stage of tumor 
development in animal studies (Hollman et al., 1996; Miller, 1996).  
In addition, Yu et al. (2006) reported that in a β-carotene-linoleate system, 
crude protein showed antioxidant activity and Li et al. (2007) and Kishk et al. 
(2007) reported that polysaccharides showed also inhibitory activity in β-
carotene-linoleate model system. Chuanguang et al. (2002) reported that 
Misgurnus anguillicaudatus polysaccharides have ability to remove O2●⎯, HO●, 
H2O2 and other oxygen active compounds. Polysaccharides, which are widely 
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distributed in animals, plants, and microorganisms, have been demonstrated to 
play an important role as dietary free-radical scavenger for the prevention of 
oxidative damage (Blander et al., 2003; Harman, 1993; Liu et al., 1997).  
As we known, both, S. crispus and S. arvensis contain such as phenolic and 
flavonoids, thereby, the purpose of this work is to evaluate the antioxidant 
activity of the extracts on the oxidative potential. 
1.7 Angiogenesis 
1.7.1 Definition and Process of Angiogenesis 
Angiogenesis can be defined as the process by which new blood vessel form 
from pre-existing vessel, which is controlled by certain chemicals produced in 
the body. The other chemicals stopped the process called angiogenesis 
inhibitors. The angiogenesis process consists of the following steps, beginning 
with activation of endothelial cells by growth factors, followed by enzymatic 
degradation of basement membrane, detachment of endothelial cells from 
adhesion proteins, endothelial cell migration into the perivascular spaces and 
proliferation, and final new vessels formation. The process is regulated by 
various growth factors and cytokines. Vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), tumor necrosis factor alpha 
(TNF-a) and interleukin-8 (IL-8) are the potent angiogenic growth factors 
(Brooks et al., 1999; Huang and Zheng, 2006; Mochizuki et al., 2007). 
 
Angiogenesis plays an important role in the growth and metastasis of tumor and 
several chronic inflammatory diseases including rheumatoid arthritis and 
proliferative diabetic retinopathy. Meanwhile many ischemic diseases for 
examples ischemic coronary artery disease, critical limb ischemia and brain 
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infarction may benefit from the induction of angiogenesis. Inhibition of 
angiogenesis has been recognized as a promising therapeutic approach for the 
control of tumor or cancer growth and metastasis and chronic inflammatory 
diseases. Tumor or chronic inflammatory diseases cannot grow or spread 
without the formation of the new blood vessels, the oxygen and nutrients be 
brought into cells via blood vessels, allowing the cells to grow, invade nearby 
tissue, spread to other part of the body, and form new cells colonies (Huang 
and Zheng, 2006, Sheeja et al., 2007, Sylvia et al., 2003, Tsuneki et al., 2005). 
1.7.2 The Relationship between Antioxidants and Antiangiogenic Agents 
A number of antiangiogenesis compounds have been recognized and many 
have antioxidative properties. Matsubara et al. (2005) reported that nasunin; an 
antioxidant anthocyanin isolated from eggplant peels was demonstrated as an 
angiogenesis inhibitor. They also implied that nasunin may also be useful to 
prevent angiogenesis related diseases. Huang and Zheng (2006) reported that 
rosmarinic acid inhibited angiogenesis of human umbilical vein endothelial cells. 
Rosmarinic acid, a water soluble polyphenolic compound which is isolated from 
medicinal plants has been reported to have biological activities such as anti-
oxidative, anti-inflammatory and anti-depressive activities. 
 
Several flavonoids that are more widely distributed in the plant kingdom, 
including 3-hydroxyflavone, 3′,4′-dihydroxyflavone, 2′,3′-dihydroxyflavone, 
fisetin, apigenin and luteolin have ability to inhibit the in vitro angiogenesis 
process (Fotsis et al., 1997 cited in Mukherjee et al., 1999; Engelmann et al., 
2002). Mukherjee et al. (1999) reported other flavonoids including genistein and 
daidzein, an isoflavone have ability in inhibiting of angiogenesis process. 
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Meanwhile Kim et al. (2006) reported flavonol of myricetin, quercetin, 
kaempferol and galangin can also inhibit angiogenesis process. Previously, Tan 
et al. (2003) reported that quercetin which is found in many fruits and 
vegetables, as well as olive oil, red wine, and tea, possesses antiangiogenic 
potential. Various pharmacological activities of quercetin have been 
demonstrated including antioxidation by scavenging free radicals, prevention of 
atherosclerosis, and chronic inflammation. Some of the earlier antiangiogenic 
compounds identified were steroids, including progestin, medroxyprogesterone 
acetate (MPA), the glucocorticoids, dexamethasone and cortisone (Williams et 
al., 1999). The other antiangiogenesis compound is squalamine, a natural 
amino sterol purified and characterized from tissues of the dogfish shark 
(Williams et al., 1999). 
 
Antiangiogenic activity of the herb extracts was recently reported by Song et al. 
(2003). In this study it was reported that Phellinus linteus extract showed strong 
antiangiogenic and antioxidant activity. The researchers suggested that 
antioxidant and anti-angiogenic activities of Phellinus linteus would be partly 
responsible for its anti-tumor effect. In vitro assay using human endothelial cells 
of edible berry extracts showed that the extracts impaired angiogenesis (Bagchi 
et al., 2004). Berries are rich in anthocyanins, compounds that provide 
pigmentation to fruits and serve as natural antioxidants. Anthocyanins also 
serve as anti-inflammatory, anti-mutagenic agents and natural antioxidant. 
Extracts of Gastrodia elata rhizome demonstrated potent anti-angiogenic 
activity in the CAM assay (Ahn et al., 2007). Rhizome of Gastrodia elata Blume 
is a traditional herbal medicine in Oriental countries. Several phenolic 
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compounds, such as 4-hydroxybenzyl alcohol, 4-hydroxybenzaldehyde, 4-
hydroxy-3-methoxybenzaldehyde and gastrodin [4-(β-D-glucopyranosyl)benzyl 
alcohol] have been identified from this plant. 
Chemical structures of a variety of phytochemicals exhibiting antiangiogenic 
activity are presented in Fig. 1.3. 
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Fig. 1.3 Chemical structures of a variety of phytochemicals exhibiting 
antiangiogenic activity 
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1.8 Drug Stability 
1.8.1 General Concept in Drug Stability 
“The purpose of stability tests is to provide evidences on how the quality of a 
drug substance or drug product varies with time under the influence of a variety 
of environmental factors such as temperature, humidity, and light, as well as to 
establish a re-test period for the drug substance or a shelf life for the drug 
product and recommended storage conditions” (ICH, 2003). 
 
“Stability is one of the most important factors, which determine whether a 
compound or mixture of compounds can be developed into a therapeutically 
useful pharmaceutical product. The recognition of this concept, along with ability 
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to optimize drug stability and product shelf life has been among the most 
significant achievements in drug research and development. The stability of a 
pharmaceutical preparation may be defined as its degree of resistance to 
chemical and physical changes. The efficacy of the preparation must remain 
constant (or change only within the limits specified by legal provision) until the 
date of expiration” (Racz, 1989).  
 
Since the herbal drug or herbal drug preparation in its entirety is regarded as 
the active substance, a mere determination of the stability of the constituents 
with known therapeutic activity will not suffice. It must also be shown, as far as 
possible e.g. by means of appropriate fingerprint chromatogram, that other 
substances present in the herbal drug or in the herbal drug preparation are 
likewise stable and that their proportional content remains constant. If herbal 
medicinal product contains several herbal drugs or preparation of several herbal 
drugs and if it is not possible to determine the stability of each active substance, 
the stability of the medicinal product should be determined by appropriate 
fingerprint chromatograms, appropriate overall methods of assay and physical 
and sensory tests or other appropriate tests. 
 
The variation in content during the proposed shelf-life of herbal medicinal 
product containing a herbal drug or herbal drug preparation whose constituents 
of known therapeutic activity should not more than 5% of the initial assay value 
whilst those whose constituents of unknown therapeutic activity should not 
exceed 10 % of the initial assay value (CPMP, 2001). 
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1.8.2 Guideline for Stability Testing of Drug Substance and Drug Product 
Stress tests of the drug substance can help to identify the likely degradation 
products, which in turn can help to establish the degradation pathway and the 
intrinsic stability of the molecule and validate the stability indicating power of the 
analytical procedure used. The nature of the stress tests will depend on the 
individual drug substance and the type of drug product involved. Stress tests 
are likely to be carried out on a single batch of the drug substance. It should 
include the effect of temperature in 10 0C increment above that for accelerated 
testing (e.g. 50°C, 60°C etc.) and humidity at 75 % or greater. The design of the 
formal stability studies for the product should be based on knowledge of the 
behavior and properties of the drug substance and from stability studies on the 
drug substance and on experience gained from clinical formulation studies. The 
likely changes on storage and the rationale for the selection of attributes to be 
tested in the formal stability studies should be stated. For long term studies, 
frequency of testing should be sufficient to establish the stability profile of the 
drug substance or drug product. Either for drug substances with a proposed re-
test period or for drug product with a proposed shelf life of at least 12 months, 
the frequency of testing at the long term storage condition should normally be 
every 3 months over the first year, every 6 months over the second year, and 
annually thereafter through the proposed re-test period for the drug substance 
or the proposed shelf life for the drug product. At the accelerated storage 
condition, a minimum of three time points, including the initial and final time 
points (e.g., 0, 3, and 6 months), from a 6-month study is recommended. In 
general, a drug substance should be evaluated under storage conditions (with 
appropriate tolerances) that test its thermal stability and, if applicable, its 
